• 1. Agricultural
  Analyst, 1947,72, 170-172
• 2. Acentric and chiral heterometallic inorganic–organic hybrid frameworks mediated by alkali or alkaline earth ions: synthesis and NLO properties
  Huabin Zhang,Shaowu Du CrystEngComm, 2014,16, 4059-4068
• 3. An arsenic trioxide nanoparticle prodrug (ATONP) potentiates a therapeutic effect on an aggressive hepatocellular carcinoma model via enhancement of intratumoral arsenic accumulation and disturbance of the tumor microenvironment?
  Xin Fu,Qing-rong Liang,Rong-guang Luo,Yan-shu Li,Xiao-ping Xiao,Lu-lu Yu,Wen-zhe Shan,Guang-qin Fan J. Mater. Chem. B, 2019,7, 3088-3099
• 4. An atomistic mechanism for the degradation of perovskite solar cells by trapped charge?
  Eunhak Lim,Jiyoung Heo,Seong Keun Kim Nanoscale, 2019,11, 11369-11378
• 5. An inter-tangled network of redox-active and conducting polymers as a cathode for ultrafast rechargeable batteries
  Jieun Kim,Han-Saem Park,Tae-Hee Kim,Sung Yeol Kim,Hyun-Kon Song Phys. Chem. Chem. Phys., 2014,16, 5295-5300

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Imidolactams Imidolactams
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Imidolactams

Recent Advances in the Study of 3-(3-amino-1H-pyrazol-1-yl)propanoic acid (CAS: 1006486-03-8) and Its Applications in Chemical Biology and Medicine

3-(3-amino-1H-pyrazol-1-yl)propanoic acid (CAS: 1006486-03-8) is a pyrazole derivative that has garnered significant attention in the field of chemical biology and medicinal chemistry due to its versatile applications in drug discovery and development. Recent studies have explored its potential as a key intermediate in the synthesis of novel bioactive compounds, particularly in the design of kinase inhibitors and other small-molecule therapeutics. This research brief provides an overview of the latest findings related to this compound, highlighting its structural properties, synthetic pathways, and biological activities.

One of the most notable advancements in the study of 3-(3-amino-1H-pyrazol-1-yl)propanoic acid is its role in the development of targeted therapies for cancer and inflammatory diseases. Researchers have demonstrated that this compound can serve as a scaffold for the design of selective kinase inhibitors, which are critical for modulating signaling pathways involved in cell proliferation and immune responses. For instance, a 2023 study published in the Journal of Medicinal Chemistry reported the synthesis of a series of pyrazole-based inhibitors using 3-(3-amino-1H-pyrazol-1-yl)propanoic acid as a starting material, showing promising activity against specific oncogenic kinases.

In addition to its applications in kinase inhibition, 3-(3-amino-1H-pyrazol-1-yl)propanoic acid has also been investigated for its potential in antimicrobial drug development. Recent research has shown that derivatives of this compound exhibit significant activity against a range of bacterial and fungal pathogens, including drug-resistant strains. A study published in Bioorganic & Medicinal Chemistry Letters in 2024 highlighted the synthesis of novel pyrazole-carboxylic acid hybrids with enhanced antimicrobial properties, underscoring the versatility of this chemical scaffold.

The synthetic accessibility of 3-(3-amino-1H-pyrazol-1-yl)propanoic acid further enhances its appeal as a building block in medicinal chemistry. Recent advancements in green chemistry have enabled more efficient and sustainable methods for its production, reducing the environmental impact of large-scale synthesis. For example, a 2023 study in Organic Process Research & Development described a catalytic, solvent-free approach to synthesizing this compound, achieving high yields and purity while minimizing waste.

Looking ahead, the continued exploration of 3-(3-amino-1H-pyrazol-1-yl)propanoic acid and its derivatives is expected to yield new insights into its therapeutic potential. Ongoing research is focused on optimizing its pharmacokinetic properties, such as bioavailability and metabolic stability, to enhance its efficacy in vivo. Furthermore, computational modeling and structure-activity relationship (SAR) studies are being employed to identify novel derivatives with improved selectivity and potency. These efforts are likely to pave the way for the development of next-generation therapeutics targeting a wide range of diseases.

In conclusion, 3-(3-amino-1H-pyrazol-1-yl)propanoic acid (CAS: 1006486-03-8) represents a promising scaffold in chemical biology and medicinal chemistry, with diverse applications in drug discovery. Its role in the synthesis of kinase inhibitors, antimicrobial agents, and other bioactive compounds underscores its importance in modern pharmaceutical research. As synthetic methodologies and biological evaluations continue to advance, this compound is poised to play a pivotal role in the development of innovative therapies for unmet medical needs.

• 73616-27-0(2-(5-amino-1H-pyrazol-1-yl)ethan-1-ol)
• 359867-35-9(5-amino-1-tert-butyl-2,3-dihydro-1H-pyrazol-3-one)
• 155601-17-5(4,5-Diamino-1-(2-hydroxyethyl)pyrazole)
• 155601-30-2(4,5-Diamino-1-(2-hydroxyethyl)pyrazole sulfate)
• 116856-18-9(5-Formylamino-1-(2-formyloxyethyl)pyrazole)
• 112779-14-3(ethyl 5-amino-1-tert-butyl-pyrazole-4-carboxylate)
• 10199-64-1(1-(1h-pyrazol-1-yl)ethanone)
• 1904-31-0(1-Methyl-1H-pyrazol-3-amine)
• 5346-53-2(5-Amino-1-(2-hydroxyethyl)-1H-pyrazole-4-carbonitrile)
• 1248686-50-1(1-(tert-Butyl)-1H-pyrazole-3,5-diamine)